Plain-English translation of NCT07355699 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing a medication called to treat marginal zone lymphoma — a type of blood cancer — in people who have never received treatment before. Researchers want to see if this medication works well when taken by itself for early-stage disease, or when combined with another immunotherapy drug for more advanced disease. The study is looking for a gentler, chemotherapy-free approach that may be easier on patients' bodies.
Currently, there is no standard first-line treatment for marginal zone lymphoma, and the chemotherapy options used today often have significant side effects. This trial exists to see if this newer medication can offer a more effective and less toxic alternative that patients might tolerate better.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will take the medication by mouth once daily for 21 days, then rest for about a week — this repeats for 6 cycles (about 6 months total). If you have more advanced disease, you'll also receive infusions of another immunotherapy drug during your treatment cycles. You'll have regular blood tests, imaging scans, and doctor visits to monitor how well the treatment is working and to watch for any side effects.
AI-generated summary from trial data · Aug 5, 2026 · Not medical advice
China